Back to Elevai Labs
(Nasdaq: ELAB)
Company Info
Overview
Management
FAQ
News
Media
Press Releases
Stock Data
SEC Filings
Governance
Contact
Investors
We rely on the capital markets for the growth of our brands.
View Stock Data
Investor Materials
Investor Presentation
Upcoming Events
Latest Press Releases
View All
October 21, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 4, 2024
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
October 3, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Latest Filings
DEF 14C
Other definitive information statements
SC TO-I
Tender offer statement by Issuer
8-K
Current report
View All
Track all markets on TradingView